News
Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.
Asianet Newsable on MSN19m
TNF Pharmaceuticals To Use AI To Recruit Patients For Drug Development: Retail Stays BearishThe company stated that the TNF-Renova partnership is analyzing data from 30,000 patients to identify high-risk patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback